Should Celgene (CELG) buy Biogen (BIIB) ? The Street's Adam Feuerstein thinks so, and offered several reasons why the deal makes sense.
Feuerstein said Celegene would benefit from Biogen's multiple sclerosis drug franchise, and would also get a head start on drugs for neurodegenerative diseases. Acquiring Biogen would also give Celgene the orphan drug Spinraza, as well access to Biogen's development of biologics.
Feuerstein believes a deal between the two would be transformative, and puts the potential deal value at $75 billion to $85 billion.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
One of pharma's biggest CEO's talks M&A action on the exchange.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.
Email
Email sent
Thank you, your email to has been sent successfully.
